I was recently interviewed by Gaston Kroub for his column, and I'm glad to share it here.
We talked about what's actually driving demand for elite patent litigators right now, how my time at Goodwin shapes the way I recruit, and where I see opportunity in the current market.
If you work in patent litigation or are thinking about a move in 2026, I think you'll find this worth your time.
I explore this further in Why I Prioritize Sleep and How I'm Improving It.
From the interview:
"Patents keep issuing, products keep launching, and companies must keep defending market share. Whether in standards or biologics, these disputes remain high-stakes and often bet-the-company, which means demand for elite patent litigators never truly softens."
"In life sciences, new drugs and biologics move through development, regulatory approval, and commercialization on a continuous cycle, and each stage creates predictable points of dispute. Hatch-Waxman litigation, biosimilar cases, and follow-on patent challenges aren't distractions from core businesses, they're central. A single patent decision can determine whether a company secures market exclusivity or loses it overnight."
This is Part I of a three-part interview. Parts II and III cover how my Biglaw background informs my recruiting approach and where the real demand is for top-tier patent litigators today. If you're considering a move in 2026, or if your firm is looking to add talent, I'd love to connect.